Transcriptional squelching re-examined

S. Natesan (), V. M. Rivera, E. Molinari and M. Gilman
Additional contact information
S. Natesan: ARIAD Gene Therapeutics, Inc.
V. M. Rivera: ARIAD Gene Therapeutics, Inc.
E. Molinari: ARIAD Gene Therapeutics, Inc.
M. Gilman: ARIAD Gene Therapeutics, Inc.

Nature, 1997, vol. 390, issue 6658, 349-350

Abstract: Abstract The introduction of a potent transcriptional activator into eukaryotic cells can paradoxically suppress the transcription of a co-introduced target gene1,2,3. This so-called ‘squelching’ is thought to result from titration of one or more general transcription factors (GTFs)4, indicating that GTFs might be in limited supply within the cell5,6. We now find that in mammalian cells, squelching is limited to episomal target genes, whereas genes integrated into cellular chromatin are immune.

Date: 1997
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/37019 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:390:y:1997:i:6658:d:10.1038_37019

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/37019

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().